Article

Good initial experience seen with dual-optic single-piece IOL

The Synchrony dual-optic single-piece IOL (Visiogen) performed well in a small initial study of this lens. The visual results were good; there were no major complications; no glare and halos after implantation; and patient satisfaction was high, according to George Beiko, MD, FRCS, who reported his experience at the American Society of Cataract and Refractive Surgery annual meeting.

The Synchrony dual-optic single-piece IOL (Visiogen) performed well in a small initial study of this lens. The visual results were good; there were no major complications; no glare and halos after implantation; and patient satisfaction was high, according to George Beiko, MD, FRCS, who reported his experience at the American Society of Cataract and Refractive Surgery annual meeting.

The IOL's construction may contribute to the good results. Dr. Beiko, of St. Catharine's, Ontario, Canada, described the lens' components:

  • Posterior stabilizers that allow the lens to center in the eye and prevent decentration.
  • Pillars that maintain the IOL in the open position and accentuate the movement of the anterior optic.
  • Displacement limiters that prevent the two optics from coming into contact with each other.

To be candidates for the IOL implant, patients had to be more than 50 years of age, have a cataract, and no astigmatism or other corneal or retinal pathologies. Intraoperatively, Dr. Beiko noted that the capsulorhexis must be 4.5 to 5 mm to cover the anterior optic. The IOL is inserted using an injector through an incision that ranges from 3.6 to 3.8 mm; the IOL itself is almost 10 mm in size.

Thus far, 13 patients have had 1 month of follow-up, 10 patients have had 3 months of follow-up, and six patients have been followed for 6 months. One month after implantation, the spherical equivalent was slightly myopic and by 6 months slightly hyperopic.

"There were no major complications. Pigment dispersion occurred in one patient," Dr. Beiko said. "My patients are very happy. My first patients were 85 years old and they were ecstatic with their distance and near vision. There have been no reports of glare and halos."

He noted that the specific results are part of the FDA trial and could not be divulged at this time.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times)  ASCRS 2025: Joaquin De Rojas, MD, leverages machine learning model to predict arcuate outcomes
(Image credit: Ophthalmology Times) ASCRS 2025: AnnMarie Hipsley, DPT, PhD, presents VESA for biomechanical simulation of presbyopia progression
Shehzad Batliwala, DO, aka Dr. Shehz, discussed humanitarian ophthalmology and performing refractive surgery in low-resource, high-risk areas at the ASCRS Foundation Symposium.
(Image credit: Ophthalmology Times) ASCRS 2025: Advancing vitreous care with Inder Paul Singh, MD
(Image credit: Ophthalmology Times) The Residency Report: Study provides new insights into USH2A target end points
Lisa Nijm, MD, says preoperative osmolarity testing can manage patient expectations and improve surgical results at the 2025 ASCRS annual meeting
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
© 2025 MJH Life Sciences

All rights reserved.